Novo and Sanofi Ventures returned to reinvest in Yale spinout Inozyme Pharma as it looks to advance its lead mineralisation disorder drug towards the clinic.

Inozyme Pharma, a US-based developer of mineralisation disorder treatments spun out of Yale University, received $67m in series A2 funding yesterday from investors including pharmaceutical firms Novo and Sanofi, the latter through its Sanofi Ventures unit. The round was co-led by Pivotal BioVenture Partners, the healthcare investment firm formed by property developer Nan Fung, and…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.